NOX Inhibitors: From Bench to Naxibs to Bedside.

Elbatreek, Mahmoud H; Mucke, Hermann; Schmidt, Harald H H W

Elbatreek, Mahmoud H; Mucke, Hermann; Schmidt, Harald H H W.

Afiliação

Elbatreek MH; Department of Pharmacology and Personalised Medicine, School of MeHNS, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. melbatreek@ppmlab.net.
Mucke H; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt. melbatreek@ppmlab.net.
Schmidt HHHW; H. M. Pharma Consultancy, Vienna, Austria.

Handb Exp Pharmacol ; 264: 145-168, 2021.

Article em En | MEDLINE | ID: mdl-32780287

Assuntos

NADPH Oxidases; Transdução de Sinais; Animais; Inibidores Enzimáticos; Camundongos; NADPH Oxidase 1; NADPH Oxidases/metabolismo; Ratos; Espécies Reativas de Oxigênio

Palavras-chave

Mechanism-based redox therapeutics; NADPH oxidases; NOX inhibitors; Reactive oxygen species; Setanaxib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transdução de Sinais / NADPH Oxidases Limite: Animals Idioma: En Revista: Handb Exp Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google